chr1-45507456-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 6P and 4B. PM1PM2PM5BP4_Strong
The NM_015506.3(MMACHC):c.182G>A(p.Arg61Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000185 in 1,613,980 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R61P) has been classified as Likely pathogenic.
Frequency
Consequence
NM_015506.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MMACHC | NM_015506.3 | c.182G>A | p.Arg61Gln | missense_variant | 2/4 | ENST00000401061.9 | |
MMACHC | NM_001330540.2 | c.11G>A | p.Arg4Gln | missense_variant | 2/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MMACHC | ENST00000401061.9 | c.182G>A | p.Arg61Gln | missense_variant | 2/4 | 2 | NM_015506.3 | P1 | |
MMACHC | ENST00000616135.1 | c.11G>A | p.Arg4Gln | missense_variant | 2/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000125 AC: 19AN: 152100Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000144 AC: 36AN: 249474Hom.: 0 AF XY: 0.000185 AC XY: 25AN XY: 135356
GnomAD4 exome AF: 0.000191 AC: 279AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.000199 AC XY: 145AN XY: 727240
GnomAD4 genome AF: 0.000125 AC: 19AN: 152100Hom.: 0 Cov.: 31 AF XY: 0.000135 AC XY: 10AN XY: 74294
ClinVar
Submissions by phenotype
Cobalamin C disease Uncertain:4
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 16, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 12, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 61 of the MMACHC protein (p.Arg61Gln). This variant is present in population databases (rs201777449, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with MMACHC-related conditions. ClinVar contains an entry for this variant (Variation ID: 533860). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 04, 2022 | - - |
See cases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Nov 14, 2019 | ACMG classification criteria: PM2, BP4 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at